Skip to content

Brain Cancer Health Center

Medical Reference Related to Brain Cancer

  1. Childhood Astrocytomas Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Treatment of Recurrent Childhood High-Grade Astrocytomas

    Most patients with high-grade astrocytomas or gliomas will eventually have tumor recurrence, usually within 3 years of original diagnosis but perhaps many years after initial treatment. Disease may recur at the primary tumor site, at the margin of the resection/radiation bed, or at noncontiguous central nervous system sites. Systemic relapse is rare but may occur. At the time of recurrence, a complete evaluation for extent of relapse is indicated for all malignant tumors. Biopsy or surgical resection may be necessary for confirmation of relapse because other entities, such as secondary tumor and treatment-related brain necrosis, may be clinically indistinguishable from tumor recurrence. The need for surgical intervention must be individualized on the basis of the initial tumor type, the length of time between initial treatment and the reappearance of the mass lesion, and the clinical picture. Patients for whom initial treatment fails may benefit from additional treatment.[1]

  2. Childhood Astrocytomas Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Treatment of Recurrent Childhood Low-Grade Astrocytomas

    Childhood low-grade astrocytomas may recur many years after initial treatment. Recurrent disease is usually at the primary tumor site, although multifocal or widely disseminated disease to other intracranial sites and to the spinal leptomeninges has been documented.[1,2] Most children whose low-grade fibrillary astrocytomas recur will harbor low-grade lesions; however, malignant transformation is possible.[3] Surveillance imaging will frequently identify asymptomatic recurrences.[4]At the time of recurrence, a complete evaluation to determine the extent of the relapse is indicated. Biopsy or surgical resection may be necessary for confirmation of relapse because other entities, such as secondary tumor and treatment-related brain necrosis, may be clinically indistinguishable from tumor recurrence. The need for surgical intervention must be individualized on the basis of the initial tumor type, the length of time between initial treatment and the reappearance of the mass lesion, and the

  3. Neuroblastoma Screening (PDQ®): Screening - Health Professional Information [NCI] - nci_ncicdr0000062795-nci-header

    This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Neuroblastoma Screening

  4. Neuroblastoma Screening (PDQ®): Screening - Health Professional Information [NCI] - Questions or Comments About This Summary

    If you have questions or comments about this summary, please send them to Cancer.gov through the Web site's Contact Form. We can respond only to email messages written in English.

  5. Astrocytoma

    Important It is possible that the main title of the report Astrocytoma is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report. ...

  6. Pituitary Tumors Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Nonfunctioning Pituitary Tumors Treatment

    Standard Treatment Options for Nonfunctioning Pituitary TumorsStandard treatment options for nonfunctioning pituitary tumors include the following:Surgery (preferably with a transsphenoidal approach) followed by close observation with radiation therapy reserved for recurrence.[1,2]Radiation therapy.[1,2,3]Surgery and postoperative radiation therapy.[1,2]The selection of treatment for patients with nonfunctioning (endocrine-inactive) tumors will depend on tumor size, the progressive course of the disease, and anatomical structures affected by the tumor extension. The majority of patients present with suprasellar extension and visual field deficits. In addition, many have hormone deficits prior to treatment. The initial treatment of patients with gonadotroph adenomas is usually by transsphenoidal surgery, particularly if the adenoma presents with neurological symptoms, because the effect of radiation therapy occurs too slowly, and no reliable medical therapy exists.[4]Surgical

  7. Arachnoid Cysts

    Important It is possible that the main title of the report Arachnoid Cysts is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report. ...

  8. Neuroblastoma Screening (PDQ®): Screening - Health Professional Information [NCI] - Get More Information From NCI

    Call 1-800-4-CANCERFor more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 a.m. to 8:00 p.m., Eastern Time. A trained Cancer Information Specialist is available to answer your questions.Chat online The NCI's LiveHelp® online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 8:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer. Write to usFor more information from the NCI, please write to this address:NCI Public Inquiries Office9609 Medical Center Dr. Room 2E532 MSC 9760Bethesda, MD 20892-9760Search the NCI Web siteThe NCI Web site provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support

  9. Neuroblastoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - nci_ncicdr0000062786-nci-header

    This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Neuroblastoma Treatment

  10. Childhood Brain Stem Glioma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Recurrent Childhood Brain Stem Glioma

    Diffuse Intrinsic Pontine GliomasGiven the dismal prognosis for patients with diffuse intrinsic pontine glioma, progression of the pontine lesion is anticipated generally within 1 year from initial radiation therapy. In most cases, biopsy at the time of clinical or radiologic progression is neither necessary nor recommended. To date, no salvage regimen has been shown to extend survival. Patients should be considered for entry into trials of novel therapeutic approaches because there are no standard agents that have demonstrated a clinically significant activity. Concomitant palliative care should be provided for these patients whether or not disease-directed therapy is administered. Focal or Low-Grade Brain Stem GliomasAt the time of recurrence, a complete evaluation to determine the extent of the relapse may be indicated for selected low-grade lesions. Biopsy or surgical resection should be considered for confirmation of relapse when other entities such as secondary tumor and

Displaying 41 - 50 of 156 Articles << Prev Page 1 2 3 4 5 6 7 8 9 10 Next >>

Today on WebMD

doctor and patient
How to know when it’s time for home care
doctory with x-ray
Here are 10 to know.
 
sauteed cherry tomatoes
Fight cancer one plate at a time.
Lung cancer xray
See it in pictures, plus read the facts.
 
Malignant Gliomas
Article
Pets Improve Your Health
SLIDESHOW
 
Headache Emergencies
Video
life after a brain tumor
VIDEO
 

Would you consider trying alternative or complementary therapies?